Acasti Pharma Other Long-Term Assets 2014-2024 | GRCE

Acasti Pharma other long-term assets from 2014 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Acasti Pharma Annual Other Long-Term Assets
(Millions of US $)
2024 $
2023 $
2022 $
2021 $
2020 $
2019 $0
2018 $0
2017 $
2016 $
2015 $
2015 $
2014 $
2014 $
2013 $
2013 $
Acasti Pharma Quarterly Other Long-Term Assets
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30 $0
2020-03-31
2019-12-31 $0
2019-09-30 $0
2019-06-30 $0
2019-03-31 $0
2018-12-31 $0
2018-09-30 $0
2018-06-30 $0
2018-03-31 $0
2017-12-31 $0
2017-09-30
2017-06-30
2017-02-28
2016-11-30
2016-08-31
2016-05-31
2016-03-31
2016-02-29
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2014-02-28
2013-12-31
2013-09-30
2013-06-30
2013-03-31
Sector Industry Market Cap Revenue
Medical MED-GENERIC DRG $0.033B $0.000B
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
Stock Name Country Market Cap PE Ratio
Merck (MKKGY) Germany $21.306B 23.25
New York Community Bancorp (FLG) United States $4.269B 0.00